Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;61(Suppl 3):51-56.
doi: 10.20471/acc.2022.61.s3.7.

ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER

Jure Murgić  1 , Ana Fröbe  1   2 , Amarnath Challapalli  3 , Amit Bahl  3
Affiliations
Review

ROLE OF ANDROGEN RECEPTOR-TARGETED AGENTS IN LOCALIZED PROSTATE CANCER

Jure Murgić et al. Acta Clin Croat. 2022 Oct.

Abstract

Anti-androgen therapy continues to be a basic pilar of treatment for both localized and metastatic prostate cancer. The advent of new generation of androgen receptor targeted agents (ARTA) transformed the care of patients with advanced disease. After such a success, the steps were taken to incorporate a new generation of ARTAs into the treatment landscape of localized prostate cancer. High-risk prostate cancer represents the most aggressive form of localized disease with significant metastatic potential and poor outcome. Here, the impact of novel therapies will likely be profound and transforming. This clinical space has already been a showcase for multidisciplinary treatment where the combination of local therapies with systemic treatment gradually improved patient outcomes and the chances of cure. The most recent step in redefining the treatment of localized disease is the adoption of novel ARTAs moving forward the multidisciplinary platform. In this narrative review, we discuss current clinical evidence supporting the use of novel ARTAs in patients with localized high-risk prostate cancer and cover recent developments in biomarker-driven strategies for treatment individualization in this clinical context.

Keywords: Radiotherapy (RT); abiraterone; androgen deprivation therapy (ADT); androgen receptor; androgen receptor targeted agents (ARTAs); enzalutamide; prostate cancer.

PubMed Disclaimer

References

    1. Pagliarulo V, Bracarda S, Eisenberger MA, Mottet N, Schröder FH, Sternberg CN, et al. Contemporary Role of Androgen Deprivation Therapy for Prostate Cancer. Eur Urol. 2012. January;61(1):11–25. 10.1016/j.eururo.2011.08.026 - DOI - PMC - PubMed
    1. Crawford ED, Heidenreich A, Lawrentschuk N, Tombal B, Pompeo ACL, Mendoza-Valdes A, et al. Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations. Prostate Cancer Prostatic Dis. 2019. March;22(1):24–38. 10.1038/s41391-018-0079-0 - DOI - PMC - PubMed
    1. Zong Y, Goldstein AS. Adaptation or selection—mechanisms of castration-resistant prostate cancer. Nat Rev Urol. 2013. February;10(2):90–8. 10.1038/nrurol.2012.237 - DOI - PubMed
    1. Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017. 10.1016/j.eururo.2016.07.032 - DOI - PMC - PubMed
    1. Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022. March 24;386(12):1132–42. 10.1056/NEJMoa2119115 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources